Evommune (NYSE:EVMN) Raised to “Hold” at UBS Group

Evommune (NYSE:EVMN) was upgraded by equities researchers at UBS Group to a “hold” rating in a research note issued on Sunday, Zacks reports.

A number of other equities analysts also recently weighed in on EVMN. William Blair downgraded shares of Evommune from an “outperform” rating to a “market perform” rating in a report on Monday, June 29th. Needham & Company LLC began coverage on shares of Evommune in a research note on Wednesday, August 26th. They issued a “buy” rating and a $28.00 price target for the company. Morgan Stanley cut their price target on shares of Evommune from $55.00 to $26.00 and set an “overweight” rating for the company in a research note on Tuesday, June 30th. Weiss Ratings downgraded shares of Evommune from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 11th. Finally, Stifel Nicolaus set a $30.00 price objective on shares of Evommune in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.80.

Evommune Stock Down 3.1%

NYSE:EVMN opened at $5.87 on Friday. The firm has a market capitalization of $212.85 million and a price-to-earnings ratio of -0.53. Evommune has a twelve month low of $5.85 and a twelve month high of $33.20. The stock’s 50 day moving average price is $10.93 and its two-hundred day moving average price is $16.89.

Evommune (NYSE:EVMN) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.21). As a group, analysts anticipate that Evommune will post -3.29 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in EVMN. Squarepoint Ops LLC acquired a new position in shares of Evommune during the 2nd quarter worth approximately $634,000. Velan Capital Investment Management LP raised its stake in Evommune by 1.1% in the 2nd quarter. Velan Capital Investment Management LP now owns 451,255 shares of the company’s stock valued at $5,997,000 after acquiring an additional 5,000 shares during the period. Bank of New York Mellon Corp bought a new stake in Evommune in the 2nd quarter valued at $340,000. Defilade Capital Management L.P. lifted its holdings in Evommune by 215.0% during the 1st quarter. Defilade Capital Management L.P. now owns 678,589 shares of the company’s stock valued at $15,601,000 after purchasing an additional 463,171 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in Evommune during the 1st quarter valued at $10,308,000.

Evommune Company Profile

Evommune, Inc is a clinical-stage biotechnology company focused on developing new treatments for immune-mediated inflammatory diseases. The company’s research is centered on identifying therapies that address the underlying biological mechanisms driving chronic inflammation rather than primarily treating symptoms.

Evommune is advancing a pipeline of investigational medicines designed for conditions with significant unmet medical needs, including dermatologic and other inflammatory disorders.